Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:04:36.896Z.
Calculation as of: 2026-10-06T22:04:36.896Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9ec8996c3a848f33a2c42fb16e066100176f843ed6f4363e42c2f797510b2bab
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.02B
PE Ratio
6.85
TTM Avg
15.39
3Y Avg
40.25
5Y Avg
40.25
Market Cap
$1.97B
PE Ratio
14.76
TTM Avg
29.48
3Y Avg
184.64
5Y Avg
184.64
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.02B | N/A | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 6.85 | 15.39 | 40.25 | 40.25 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 7.63 | 7.63 | 7.63 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 28.16 | 33.84 | 41.30 | 55.21 |
| Vericel Corporation (VCEL)vs › | $2.05B | 85.61 | 135.31 | 1187.07 | 1145.73 |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | N/A | 34.42 | 34.42 | 34.42 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 14.76 | 29.48 | 184.64 | 184.64 |
| Alvotech (ALVO)vs › | $2.08B | N/A | 33.55 | 33.55 | 33.55 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$41.43
Forward EPS (Est.)
$-0.22
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2017-12-29 | 209.99 |
| 2017-12-28 | 215.86 |
| 2017-12-27 | 216.37 |
| 2017-12-26 | 212.08 |
| 2017-12-22 | 218.79 |
| 2017-12-21 | 217.21 |
| 2017-12-20 | 213.71 |
| 2017-12-19 | 217.44 |
| 2017-12-18 | 224.49 |
| 2017-12-15 | 214.11 |
| 2017-12-14 | 209.37 |
| 2017-12-13 | 207.67 |
| 2017-12-12 | 217.55 |
| 2017-12-11 | 212.81 |
| 2017-12-08 | 217.04 |
| 2017-12-07 | 221.56 |
| 2017-12-06 | 211.91 |
| 2017-12-05 | 217.89 |
| 2017-12-04 | 228.16 |
| 2017-12-01 | 223.76 |
| 2017-11-30 | 227.82 |
| 2017-11-29 | 226.35 |
| 2017-11-28 | 228.16 |
| 2017-11-27 | 230.14 |
| 2017-11-24 | 231.04 |
| 2017-11-22 | 226.75 |
| 2017-11-21 | 230.87 |
| 2017-11-20 | 235.89 |
| 2017-11-17 | 231.38 |
| 2017-11-16 | 227.14 |
| 2017-11-15 | 234.54 |
| 2017-11-14 | 238.04 |
| 2017-11-13 | 244.13 |
| 2017-11-10 | 231.60 |
| 2017-11-09 | 215.91 |
| 2017-11-08 | 215.58 |
| 2017-11-07 | 209.65 |
| 2017-11-06 | 207.79 |
| 2017-11-03 | 207.79 |
| 2017-11-02 | 190.69 |
| 2017-11-01 | 181.04 |
| 2017-10-31 | 179.06 |
| 2017-10-30 | 173.02 |
| 2017-10-27 | 160.38 |
| 2017-10-26 | 155.47 |
| 2017-10-25 | 161.12 |
| 2017-10-24 | 166.20 |
| 2017-10-23 | 154.29 |
| 2017-10-20 | 153.95 |
| 2017-10-19 | 154.97 |
| 2017-10-18 | 157.62 |
| 2017-10-17 | 162.87 |
| 2017-10-16 | 163.32 |
| 2017-10-13 | 163.66 |
| 2017-10-12 | 168.57 |
| 2017-10-11 | 173.53 |
| 2017-10-10 | 170.37 |
| 2017-10-09 | 168.17 |
| 2017-10-06 | 165.69 |
| 2017-10-05 | 171.90 |
| 2017-10-04 | 174.27 |
| 2017-10-03 | 180.42 |
| 2017-10-02 | 181.55 |
